ABSTRACT:The effects of [4-(6-allyl-methyl-amino-hexyloxy)-2-fluoro-phenyl]-(4-bromophenyl)-methanone fumarate (Ro 48-8071), an inhibitor of 2,3-oxidosqualene:lanosterol cyclase (cyclase), were evaluated on CYP3A4 and CYP2B6 mRNA content in primary cultured human hepatocytes. In seven hepatocyte culture preparations, 24-h treatment with 3, 10, or 30 M Ro 48-8071 produced median increases in CYP3A4 mRNA content that were 2.2-, 7.1-, and 8.5-fold greater than untreated control, respectively, and produced increases in CYP2B6 mRNA content that were 3.0-, 4.6-, and 3.4-fold greater than control, respectively. Increases in CYP3A4 immunoreactive protein content were also measured in Ro 48-8071-treated hepatocytes. To evaluate the effects of cyclase inhibitor treatments further, a pregnane X receptor ( A primary mode of defense that is used by animals against their chemical environments involves recognition by a "xenobiotic-sensing" receptor followed by the induction of phase I and phase II xenobiotic-metabolizing enzymes, as well as "phase III" transporters. As the archetype of this mechanism, many xenobiotics bind to the pregnane X receptor (PXR), owing to the receptor's unusually accommodating ligand-binding pocket (Watkins et al., , 2003. On ligand binding, PXR, in partnership with the retinoic X receptor, is transformed into an active transcription factor that increases the expression of target genes, which include members of the CYP3A family (e.g., CYP3A23 in rat, CYP3A11 in mouse, and CYP3A4 in human). These CYP3A enzymes catalyze the phase I metabolism of numerous xenobiotic substrates, including a large number of clinically used drugs (Quattrochi and Guzelian, 2001).In addition to serving as a xenobiotic recognition and metabolizing system, PXR and CYP3A enzymes are increasingly perceived to function in the metabolism of endogenous molecules. For example, the cholestatic secondary bile acid, lithocholate, both activates PXR and is a substrate for CYP3A (Staudinger et al., 2001;Xie et al., 2001). We have used chemical inhibitors of various steps of the cholesterol biosynthetic pathway as an approach for identifying endogenous modulators of hepatic cytochrome P450 expression (Fig. 1). In this regard, we have reported that inhibitors of squalene synthase (e.g., squalestatin 1), the first committed step in cholesterol biosynthesis, selectively induce CYP2B expression in primary cultured rat hepatocytes and rat liver through a mechanism that requires the